Intravaginal use of natural micronised progesterone to prevent pre-term birth: A randomised trial in India

Journal of Obstetrics and Gynaecology

Volumn 29, Issue 6, 2009, Pages 493-498

  Majhi, P ^a   Bagga, R ^b   Kalra, J ^b   Sharma, M ^b  

^a CHRISTIAN MEDICAL COLLEGE   (India)

^b POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Intravaginal; Pre term birth; Prevention; Progesterone

Indexed keywords

METRONIDAZOLE; PROGESTERONE;

ADULT; ARTICLE; BEDTIME DOSAGE; BIRTH WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GESTATIONAL AGE; HUMAN; INDIA; MAJOR CLINICAL STUDY; PREGNANCY OUTCOME; PREMATURE LABOR; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; STATISTICAL ANALYSIS; VAGINA DISCHARGE; VAGINAL DISCOMFORT; VAGINITIS;

ADMINISTRATION, INTRAVAGINAL; ADULT; FEMALE; HUMANS; INDIA; PREGNANCY; PREMATURE BIRTH; PROGESTERONE; PROGESTINS; RECURRENCE; YOUNG ADULT;

EID: 69349093234     PISSN: 01443615     EISSN: 13646893     Source Type: Journal    
DOI: 10.1080/01443610902980878     Document Type: Article

References (22)

1. Cicinelli E, Schonauer LM, Galantino P, Matteo MG, Cassetta R, Pinto V. 2000. Mechanisms of uterine specificity of vaginal progesterone. Human Reproduction 15:159-165. (Pubitemid 30410137)
2. Creasy RK. 1993. Pre-term birth prevention: where are we? American Journal of Obstetrics and Gynecology 168:1223-1230.
3. da Fonseca EB, Bittar RE, Carvalho MH, Zugaib M. 2003. Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous pre-term birth in women at increased risk: a randomized placebo-controlled double-blind study. American Journal of Obstetrics and Gynecology 188:419-424. (Pubitemid 36249980)
4. DeFranco EA, O'Brien JM, Adair CD, Lewis DF, Hall DR, Fusey et al. 2007. Vaginal progesterone is associated with a decrease in risk for early pre-term birth and improved neonatal outcome in women with a short cervix: a secondary analysis from a randomized, double-blind, placebo-controlled trial. Ultrasound in Obstetrics and Gynecology 30:697-705.
5. Dodd JM, Flenady V, Cincotta R, Crowther CA. 2006. Prenatal administration of progesterone for preventing pre-term birth. Cochrane Database Syst Rev 1:CD004947.
6. Fuchs AR, Fuchs F. 1984. Endocrinology of human parturition: a review. British Journal ofObstetrics and Gynaecology 91:948-967.
7. Johnson JW, Austin KL, Jones GS, Davis GH, King TM. 1975. Efficacy of 17alpha-hydroxyprogesterone caproate in the prevention of premature labor. New England Journal of Medicine 293:675-680.
8. Keirse MJ. 1990. Progestogen administration in pregnancy may prevent pre-term delivery. British Journal of Obstetrics and Gynaecology 97:149-154.
9. Levy T, Gurevitch S, Bar-Hava I, Ashkenazi J, Magazanik A, Homburg R et al. 1999. Pharmacokinetics of natural progesterone administered in the form of a vaginal tablet. Human Reproduction 14:606-610. (Pubitemid 29131233)
10. Lockwood CJ, Senyei AE, Dische MR, Casal D, Shah KD, Thung SN et al. 1991. Fetal fibronectin in cervical and vaginal secretions as a predictor of pre-term delivery. New England Journal of Medicine 325:669-674.
11. Mackenzie R, Walker M, Armson A, Hannah ME. 2006. Progesterone for the prevention of pre-term birth among women at increased risk: a systematic review and meta-analysis of randomized controlled trials. American Journal of Obstetrics and Gynecology 194:1234-1242.
12. Meis PJ, Klebanoff M, Thom E, Dombrowski MP, Sibai B, Moawad AH et al. 2003. Prevention of recurrent pre-term delivery by 17 alpha-hydroxyprogesterone caproate. New England Journal of Medicine 348:2379-2385. (Pubitemid 36682816)
13. Nugent RP, Krohn MA, Hillier SL. 1991. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation. Journal of Clinical Microbiology 29:297-301.
14. O'Brien JM, Adair CD, Lewis DF, Hall DR, Defranco EA, Fusey S et al. 2007. Progesterone vaginal gel for the reduction of recurrent pre-term birth: primary results from a randomized, double-blind, placebo-controlled trial. Ultrasound in Obstetrics and Gynecology 30:687-696. (Pubitemid 47612689)
15. Papiernick-Berkhauer E. 1970. Double blind study of an agent to prevent preterm delivery among women at increased risk. In: Schering, editor. Series 4. p 65-68.
16. Pschirrer ER, Monga M. 2000. Risk factors for pre-term labor. Clinical Obstetrics and Gynecology 43:727-734.
17. Rai P, Rajaram S, Goel N, Ayalur Gopalakrishnan R, Agarwal R, Mehta S. 2009. Oral micronized progesterone for prevention of pre-term birth. International Journal of Gynaecology and Obstetrics 104:40-43.
18. Sanchez-Ramos L, Kaunitz AM, Delke I. 2005. Progestational agents to prevent pre-term birth: a meta-analysis of randomized controlled trials. Obstetrics and Gynecology 105:273-279. (Pubitemid 40229441)
19. Spong CY, Meis PJ, Thom EA, Sibai B, Dombrowski MP, Moawad AH et al. 2005. Progesterone for prevention of recurrent pre-term birth: impact of gestational age at previous delivery. American Journal of Obstetrics and Gynecology 193:1127-1131. (Pubitemid 41285506)
20. Tavaniotou A, Smitz J, Bourgain C, Devroey P. 2000. Comparison between different routes of progesterone administration as luteal phase support in infertility treatments. Human Reproduction Update 6:139-148. (Pubitemid 30182295)
21. Tognoni G, Ferrario L, Inzalaco M, Crosignani PG. 1980. Progestogens in threatened abortion. Lancet 2:1242-1243.
22. Yemini M, Borenstein R, Dreazen E, Apelman Z, Mogilner BM, Kessler I et al. 1985. Prevention of premature labor by 17 alpha-hydroxyprogesterone caproate. American Journal of Obstetrics and Gynecology 151:574-577. (Pubitemid 15049683)